New drug shows sustained benefit at 2 years in rare blood cancer
the ONA take:
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia, a rare blood cancer.
In addition, 95% of patients receiving the newly approved drug are experiencing progression-free survival 2 years after initiating treatment. When progression did occur, it began at a median of 9.6 months after the start of treatment.
Waldenstrom macroglobulinemia is caused by an abnormality in the B lymphocytes in bone marrow that causes the overproduction of IgM, an immunoglobulin protein that thickens the blood.
It is driven by the MYD88 and CXCR4 genetic mutations. MYD88 mutation triggers abnormal activity of Bruton’s tyrosine kinase. Ibrutinib targets a pathway involving Bruton’s tyrosine kinase protein.
The trial included 63 patients who had received at least one prior treatment. The drug is administered as an oral drug taken daily.
Treatment continued until the disease worsened or unacceptable toxic effects occurred. Response rate in the study refers to the degree of reduction in IgM in the blood.
Recent results from a clinical trial show that ibrutinib (Imbruvica) continued to control Waldenstrom macroglobulinemia.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Neuropathic Cancer Pain Linked to Reduced Quality of Life
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|